HOUSTON, TX / ACCESS Newswire / February 19, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP)("CNS" or the "Company"), a ...

Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company ...

January 2025, the U.S. Securities and Exchange Commission (SEC) approved amendments, both of which are now effective, to The Nasdaq Stock Market ...

B. Riley raised the firm’s price target on Globalstar (GSAT) to $60 from $4 and keeps a Buy rating on the shares to account for the 1-for-15 ...

The Securities and Exchange Commission (SEC) recently approved rule changes proposed by The Nasdaq Stock Market LLC that impact companies ...

A good amount of retail investor ownership and a share price north of $1,000 makes this brand-name company the most-logical ...

MENLO PARK, Calif. - Cyngn Inc. (NASDAQ:CYN), a developer of autonomous vehicle technology with a current market capitalization of $3.23 million, has announced a 1-for-150 reverse stock split of its ...

Under the reverse stock split that took effect after the markets closed Monday, 15 shares of Globalstar stock will be ...

Feb. 13, 2025 /PRNewswire/ -- Cyngn Inc. (the "Company" or "Cyngn") (Nasdaq: CYN) today announced that it will proceed with a 1-for-150 reverse stock split ("Reverse Stock Split") of its ...

CNS Pharmaceuticals (CNSP) announced a 1-for-50 reverse split of its common stock. Beginning on February 21, 2025, the Company’s common stock ...

The reverse stock split is intended to regain compliance with the minimum bid price requirement of $1.00 per share of the Company’s common stock for continued listing on The Nasdaq Capital Market.